Literature DB >> 1986009

Nature of altered growth hormone secretion in hyperthyroidism.

A Iranmanesh1, G Lizarralde, M L Johnson, J D Veldhuis.   

Abstract

Hyperthyroidism is accompanied by various neuroendocrine regulatory disturbances that affect not only the thyrotropic, but also the gonadotropic, corticotropic, and somatotropic axes. To examine the nature of alterations in neuroendocrine control mechanisms that direct the somatotropic axis in hyperthyroidism, we have applied a novel deconvolution technique designed to estimate the number, amplitude, and mass of significant underlying GH secretory events after the influence of GH metabolic clearance has been removed mathematically. To this end, blood was sampled at 10-min intervals for 24 h in seven hyperthyroid and seven age-matched euthyroid men. The subsequent GH time series were assayed by immunoradiometric assay (sensitivity, 0.08 ng/mL) and submitted to quantitative deconvolution analysis. We found that hyperthyroid compared to euthyroid men 1) had significantly more GH secretory bursts per 24 h (viz. 15 +/- 1.0 vs. 10 +/- 1.1; P = 0.017); 2) secreted 3 times as much GH per burst (3.7 +/- 0.80 vs. 1.3 +/- 0.42 ng/mL distribution vol; P = 0.013); 3) achieved a maximal rate of GH secretion in each burst 2.3-fold higher than that in control men (0.14 +/- 0.028 vs. 0.060 +/- 0.015 ng/mL.min; P = 0.017); and 4) had 3.7-fold higher 24-h endogenous GH production rates (P less than 0.01). Neither hyperthyroid nor euthyroid men had significant interburst (tonic) GH secretion. We conclude that the somatotropic axis in hyperthyroid men is marked by a higher frequency of spontaneous GH secretory bursts, a higher rate of maximal GH secretion attained per burst, and a larger mass of GH released per burst. These neuroregulatory disturbances result in a nearly 4-fold increase in the 24-h production rate of GH in thyrotoxicosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986009     DOI: 10.1210/jcem-72-1-108

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  Glucose metabolism before and after radioiodine therapy of a patient with Graves' disease: Assessment by continuous glucose monitoring.

Authors:  Yun Hu; Gu Gao; Reng-Na Yan; Feng-Fei Li; Xiao-Fei Su; Jian-Hua Ma
Journal:  Biomed Rep       Date:  2017-06-21

4.  Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation.

Authors:  E Todd Schroeder; Jiaxiu He; Kevin E Yarasheski; Ellen F Binder; Carmen Castaneda-Sceppa; Shalender Bhasin; Christina M Dieli-Conwright; Miwa Kawakubo; Ronenn Roubenoff; Stanley P Azen; Fred R Sattler
Journal:  Eur J Appl Physiol       Date:  2011-07-12       Impact factor: 3.078

5.  Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.

Authors:  Patricia Molica; Sergio Oliva Nascif; Silvia Regina Correa-Silva; Larissa Bianca Paiva Cunha de Sá; José Gilberto Henriques Vieira; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

Review 6.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

7.  Clinical and endocrine features and long-term outcome of Graves' disease in early childhood.

Authors:  A T Bossowski; V Reddy; L A Perry; L B Johnston; K Banerjee; J C Blair; M O Savage
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

8.  Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Sergio Oliva Nascif; Silvia Regina Correa-Silva; Marcos Roberto Silva; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

9.  Glycemic variation in uncontrolled Graves' disease patients with normal glucose metabolism: Assessment by continuous glucose monitoring.

Authors:  Gu Gao; Feng-Fei Li; Yun Hu; Reng-Na Yan; Bing-Li Liu; Xiao-Mei Liu; Xiao-Fei Su; Jian-Hua Ma; Gang Hu
Journal:  Endocrine       Date:  2018-12-04       Impact factor: 3.633

10.  Thyroid function in children with growth hormone deficiency during long-term growth hormone replacement therapy.

Authors:  Ewelina Witkowska-Sędek; Ada Borowiec; Anna Majcher; Maria Sobol; Małgorzata Rumińska; Beata Pyrżak
Journal:  Cent Eur J Immunol       Date:  2018-10-30       Impact factor: 2.085

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.